{"id":"W4382794886","doi":"10.1016/j.annonc.2023.06.009","title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Janssen Research and Development; National Cancer Institute; Genentech; Astellas Pharma; Ipsen; Clovis Oncology; Taiho Pharmaceutical; Gilead Sciences; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Takeda Oncology; Amgen; Pfizer; Daiichi Sankyo Europe; Sanofi; Abbott Laboratories","keywords":"Medicine; Abiraterone acetate; Interim analysis; Prednisone; Prostate cancer; Hazard ratio; Internal medicine; Progression-free survival; Urology; Oncology; Chemotherapy; Confidence interval; Gastroenterology; Androgen deprivation therapy; Randomized controlled trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004731319,0.002302931,0.003920078,0.0004866361,0.0004900463,0.002084499,0.0009982983,0.00130402,0.005844492],"category_scores_gemma":[0.00362696,0.0008519933,0.003279806,0.000574764,0.001487355,0.002284022,0.0006672185,0.004834638,0.001240385],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001043623,"about_ca_system_score_gemma":0.001740216,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006700241,"about_ca_topic_score_gemma":0.001837662,"domain_scores_codex":[0.9978441,0.00144837,0.00008022521,0.0002729589,0.0001310913,0.000223316],"domain_scores_gemma":[0.9981799,0.0006279814,0.0004406095,0.0002633483,0.0000844856,0.0004037207],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9774522,0.001970688,0.0007066361,0.0002648479,0.001375936,0.0000262036,0.00004209276,0.001100883,0.001068095,0.0001986183,0.0009536814,0.01484016],"study_design_scores_gemma":[0.943039,0.05053058,0.002177158,0.00004605534,0.0009337252,0.00007800505,0.00003877734,0.0009382812,0.0003728398,0.000752811,0.00106641,0.00002633779],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9776054,0.009053243,0.001599491,0.001955705,0.001140526,0.001864986,0.001930984,0.0002846105,0.004565149],"genre_scores_gemma":[0.986227,0.00216579,0.002155137,0.001437878,0.0005844178,0.001648639,0.002176716,0.00005753235,0.003546938],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005844492,"threshold_uncertainty_score":0.02502185,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0673827402915172,"score_gpt":0.3994581347533062,"score_spread":0.332075394461789,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}